LSI USA Summit Presenting Companies | Emerging Medtech Startups

Lothar Krinke

CEO, Adraxe Corporation

Adraxe is developing a minimally invasive active implant for the treatment of drug-resistant epilepsy. The product is based on a novel stimulation technology licensed from New York University that is delivered precisely when a seizure is detected from electrodes implanted under the scalp. First-in-human clinical data has demonstrated safety and seizure burden reduction.

Isaiah Kaiser

Founder & CEO, Aeris Biosciences

Aeris Biosciences develops bio-based, highly porous biomaterials for tissue regeneration and infection prevention in complex wounds. Its Aer™ platform uses controlled surface chemistry and three-dimensional architecture to support regenerative cell integration while resisting bacterial attachment and biofilm formation.

Joel Krupa

CAO, Agents of Discovery Inc.

Agents of Discovery empowers health and life sciences organizations, cities, universities, airports, sports teams, and other innovation hubs to create place-based learning experiences guided by interactive, AI-powered avatars. Using the Agents platform, teams can support education, workforce training, and community engagement while transforming indoor and outdoor spaces into dynamic, interactive adventures.

Jason Chan

Co-Founder & Chief of Clinical Development, Agilis Robotics

Agilis Robotics aims to transform incisionless endoluminal surgery with ultra-thin, flexible robotic instruments engineered to enhance surgical precision and simplify learning. Designed to integrate seamlessly with standard endoscopes, our versatile robotic system, the Intilume™ System, seeks to empower clinicians with advanced dexterity and adaptability when managing early-stage cancers and diseases in the bladder and GI tract —unlocking new possibilities for more accessible and effective care.

Disclaimer: The Intilume™ System is not approved for sale or commercial use in any market.

Gregory Fischer

Founder & CEO, AiM Medical Robotics

AiM Medical Robotics is a Massachusetts-based neurosurgical robotics company commercializing a compact, MRI-compatible surgical robot that enables intra-operative imaging to account for brain shift and facilitate real-time monitoring of therapy delivery. AiM's platform harnesses real-time MRI to ensure precise placement of neurostimulation leads for Parkinson's patients and its versatile capabilities also support a wide range of neurosurgical procedures, including biopsies, tumor ablation, and intracranial therapeutic delivery with a >$10B market opportunity. Built on over 15 years of NIH-funded research totaling approximately $15 million, AiM's proprietary and patented technology reflects the deep expertise of its founding team that completed an $8.1 million Series A financing round funding a first-in-human clinical trial at Brigham and Women's Hospital in Boston.

Dr. Mohamed Zayed

Co-Founder & CEO, AirSeal CardioVascular

AirSeal CardioVascular is developing PADGuard™, a blood-based diagnostic for early detection of peripheral artery disease (PAD), affecting over 230 million people worldwide. Powered by a patented circulating fatty acid synthase (cFAS) biomarker and supported by clinical evidence from over 800 patients, the technology aims to improve PAD detection and enable broader applications in cardiovascular risk prediction, disease monitoring, and therapeutic response assessment.

Michael Mrochen

Co-Founder & CEO, Allotex

Allotex is pioneering a new category in presbyopia correction with its human collagen corneal inlay. With established commercial traction across Europe, Canada, and other international markets, the company is addressing a large, underserved self-pay market and scaling toward global expansion, supported by strong clinical evidence and a clear regulatory pathway.

Sean Morris

President & CEO, Amplifi Vascular

Amplifi Vascular is developing the Amplifi™ Vein Dilation System, a proprietary blood pump technology designed to enlarge veins and improve outcomes for patients requiring arteriovenous fistula (AVF) surgery. The system is intended to increase AVF eligibility, accelerate maturation, reduce failure rates, and extend primary patency. By addressing key challenges in dialysis access, Amplifi aims to improve treatment outcomes for patients with end-stage renal disease.

John Chung

President & CEO, Aposture Surgical

Aposture Surgical Corporation has developed a novel, next-generation fixation system for posterior lumbar interbody fusion, the ApostureFlex Stabilization System. The unique, patented design incorporates (i) nitinol, spring-coil rods; (ii) interbody cages; and (iii) detachable screw head modules, resulting in stability for fusion and controlled posterior flexibility that allows for more natural motion, sagittal balance, and lumbar lordosis. In a peer-reviewed study of patients in South Korea, the Gen 1 ApostureFlex demonstrated a 95+% reduction in reoperations due to adjacent segment disease after a 13-year follow-up period, proving that ApostureFlex can eliminate the biomechanical distortions of conventional rigid fixation systems.

Arctx Medical, a clinical-stage medical technology company, is developing the world’s first targeted treatment for Acute Pancreatitis (AP). Local cooling is a well-established therapy for treating acute inflammatory conditions within the body. The Arctx Cool Catheter™ (ACC) Set delivers minimally invasive, localized, and potent cooling therapy to the pancreas, intended to reduce inflammation, accelerate patient recovery, and prevent more serious complications including organ failure and death. Arctx is embarking on an IDE-approved US pivotal clinical trial for this first-ever dedicated treatment for AP. The company has also received FDA marketing authorization for use of the ACC in patient temperature management, a second and mature market for its technology.

Brett Robertson

Managing Director & CEO, ArthroLase

ArthroLase is introducing Laser Arthroplasty, a new category of joint replacement surgery - built on laser bone shaping, rather than the mechanical saw that has defined the procedure until now.

The Platform has three products, all built to work together:

HAiLO™ – A robotic platform that replaces the mechanical, flat-cut saw with laser bone shaping.
AiRO-x™ – Next-generation cementless implant, designed for the precise fit only HAiLO can deliver.
ArthroAI™ – Surgeon-synced intelligence. Real-time intraoperative decision support, built on the data every HAiLO procedure generates.

In summary, sub-millimetre laser precision (HAiLO) cuts any geometry, not just flat planes, freeing implant design from the limits of a mechanical blade for the first time. That freedom lets us redesign the implant itself: fixation features embedded directly into the bone surface, no bone cement, and more surface area for bone bonding - this is AiRO-x. The same laser and optical vision system also feed ArthroAI, surgeon-synced intelligence that reads sensor data in real time to support the surgeon’s decisions during the case, drawing on the full data set as it builds. In a world first, every cut is guided end to end by a live digital twin, giving surgeons a new level of confidence and predictability.

Eric Leuthardt

CEO, Aurenar

Aurenar is developing a non-invasive, single-use neuromodulation platform for critically ill patients. Its transauricular vagus nerve stimulation (taVNS) system targets inflammation — a primary driver of complications, mortality, and cost in the ICU. The FDA has granted Breakthrough Device Designation for the reduction of cerebral vasospasm in adults with aneurysmal subarachnoid hemorrhage (aSAH), with additional inflammation-driven indications to follow.

Souvik Paul

CEO & Founder, Aurie

Aurie holds FDA Class II De Novo clearance for the world's first safely reusable catheter system: one patented reusable catheter and an easy-to-use portable washer-disinfector with pre-packaged supplies replaces 100 single-use catheters at standard-of-care pricing, halving life-threatening infection risk and cutting catheterization waste by more than 67%. Incumbents have left the $3B intermittent catheter market stagnant for three decades with limited innovation. Two large RCTs (MultICath, COMPaRE) have now validated reuse and consumer demand for reusable alternatives to single-use catheters; Aurie is the only cleared system built to capture the shift.

Brad Hauser

CEO, Autonomix Medical, Inc.

Autonomix (Nasdaq: AMIX) is a medical device company developing a minimally invasive nerve-sensing, ablation, and verification system to advance the diagnosis and treatment of diseases involving the nervous system. The company's catheter-based microchip sensing array is designed to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies. This platform enables transvascular diagnosis and treatment of conditions affecting the peripheral nervous system. Initially focused on pancreatic cancer pain, Autonomix's technology has potential applications across multiple fields, including cardiology, renal denervation, and chronic pain management.

Lode Debrabandere

Co-Founder & CEO, AxoCell

AxoCell, Inc. is a Charleston, South Carolina-based medical nano-technology company developing drug-eluting nanofiber devices for peripheral nerve repair. Originating from IP of the Johns Hopkins Institute of NanoBioTechnology, University of Pittsburgh and SickKids-Toronto research programs, the company developed nerve repair products with superior healing capabilities. Our devices reduce scar tissue formation 3-fold and regenerate double the amount of axonal nerve fibers compared to the current leading brands. The company plans to launch its first generation devices in Q1 2027 in partnership with a leading orthopedics strategic player.

Meagan Pitcher

CEO & Co-Founder, Bairitone Health

Bairitone is developing an FDA Breakthrough Device-designated diagnostic platform that uses contact acoustic sensing and AI to identify the anatomical site and pattern of airway collapse during natural sleep at home. The platform is intended for clinicians selecting among sleep apnea therapies, including CPAP, oral appliances, surgery, and neurostimulation.

John Brumfield

CEO, Berlin Heals

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.

Alexis Peyroles

CEO, BETAGLUE THERAPEUTICS SPA

BetaGlue Therapeutics is a life sciences company that delivers radiotherapy from within. Introducing Yntradose, our proprietary product.

Marcos Sforza

CEO, BMC International Medical

BMC Health is advancing the standard of care in male urology, beginning with urinary incontinence—large, underserved markets constrained by legacy surgical solutions., Its patent-protected platform leverages novel materials and advanced design to replace complex procedures with minimally invasive, office-based therapies. BMC's urinary incontinence system is designed to outperform existing surgical alternatives on safety, simplicity, and clinical adoption. The company is building a broader pipeline across male urologic health and is advancing through global regulatory pathways, led by a team with demonstrated success commercializing implantable medical devices in the U.S. and internationally.

Carrie DiMarzio

CEO, BMI OrganBank

BMI OrganBank is advancing the OrganBank Kidney (OBK) System, a portable, automated, room-temperature preservation platform that combines continuous preservation with real-time organ viability data in a single end-to-end environment. Its mission: help every viable donated organ reach a patient. The company has received FDA Breakthrough Device Designation.

Alex Herzlinger

CEO, Brandywine MedTech Consultancy

Brandywine MedTech Consultancy specializes in helping innovators commercialize new medical technology.

Edouard Fonck

CEO, CAIRDAC

Leveraging multidisciplinary expertise in cardiac rhythm management and implantable medical devices, CAIRDAC has developed a self-sustaining leadless pacemaker based on a proprietary energy-harvesting approach. The system integrates a piezoelectric energy harvester with a miniaturized, high-efficiency ASIC dedicated to power management, enabling continuous conversion of cardiac mechanical activity into electrical energy. This architecture is designed to support device operation without reliance on a conventional battery-limited energy management system — representing a novel approach to implantable pacing systems.

Lara Zibners

Co-Founder & Chairman, Calla Lily Clinical Care

Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions.

Chance W. Leonard

CEO, Capitan Orthopedics

R. Sean Churchill, MD, MBA

Lead Surgeon Designer, Capitan Orthopedics

Today, over 2 million people a year are diagnosed with a rotator cuff injury and over 900,000+ undergo surgery to repair a primary rotator cuff tear. But there is a massive gap in the current care continuum and for far too long patients with irreparable cuff tears have suffered with limited surgical options and no long-term solution. Capitan Orthopedics, Inc., a subsidiary company of Genesis Innovation Group, has taken on the challenge of addressing one of the most common and frustrating shoulder conditions facing orthopedic surgeons today - the painful, irreparable rotator cuff tear in patients aged 25-65. Our team of expert surgeons and engineers have created a novel implant technology and a simple, reproducible procedure. The SupraSpacerTM is specifically designed for these patients - by helping maintain the humeral head centered in the joint, the implant not only reduces the risk and advancement of shoulder arthritis but removes the painful abutment of the humeral head on the undersurface of the acromion, allowing for full impingement-free range of motion.

Sebastien Ladet

CEO, Carvolix

Carvolix is a French MedTech company at commercial and clinical stage, listed on Euronext Paris (ticker: CVX). Its platform pairs AI with image-guided mini-robotic platform and biomimetic implants across three verticals — aortic (TAVIPILOT), mitral (KALIOS, MITRAPILOT) and stroke (ARTEDRONE) — addressing structural heart disease and ischemic stroke. The company’s mission is to democritize patient access to complex interventional procedures by empowering interventional cardiologists with AI-driven robotics.

Mark Alley

CEO, Cipher Surgical

OpClear is an intra operative lens cleaner. The OpClear platform uses automated CO2 flow and on-demand saline lens wash, minimizing the need for scope removal during a procedure and addressing many of the frustrations associated with visual obstructions. This rapidly clears larger visual obstructions such as fogging, misting and blood or particles from energy plumes to provide continuous vision throughout each procedure.

Moises Barbera Ramos

Founder & CEO, CLARO Surgical

CLARO Surgical's platform is an AI-powered surgical guidance system for orthopaedics and trauma, leveraging Mixed Reality to digitize the surgical field and augment it with real-time, X-ray-free navigation. The technology's current platform covers common trauma and orthopedic procedures like intramedullary nailing or plating, reduces drilling and locking time by 86%, improves success rate by 87%, and has already been used to operate on 12 patients successfully.

Regina Atim

CEO & Chief Innovation Officer, Clinicians Touch ALLYVE

Clinicians Touch ALLYVE is developing a wearable maternal bracelet and corresponding application that collects patient-generated data during pregnancy. The device will empower tracking of key data that can be shared with providers to improve outcomes during pregnancy.

Vinayak Rengan

Founder & CEO, Curium Life

Curium Life is developing surgical AI that converts laparoscopic and robotic video into useful intraoperative information. Its flagship technology, SurgiMeasure, is being developed to provide real-time anatomical measurements from standard surgical video. It combines instrument recognition, depth estimation and geometric scaling to translate image dimensions into physical measurements, addressing the absence of a reliable scale in minimally invasive surgery. Potential applications include bowel-length measurement, hernia-defect assessment and mesh sizing. Designed to work across camera platforms, SurgiMeasure is undergoing validation. It forms part of Curium Life's broader effort to develop surgical foundation models that recognise instruments, anatomy, operative phases and actions.

Yuval Mandelbaum

CEO, Discure Technologies

Discure Technologies is a stealth-mode startup dedicated to providing relief for millions of people with debilitating back pain. The company is developing a minimally invasive device intended to treat discogenic back pain by reversing degenerative disk disease, a condition associated with over 35% of all low back pain cases. The technology targets the underlying cause of the disease, restoring the disk's healthy function and eliminating pain via a bioelectronic approach.

Marcin Golebicki

CEO, EBAMed

EBAMed is developing CardioKit™, a first-of-its-kind NON-INVASIVE CARDIAC ABLATION AND REAL-TIME MOTION MANAGEMENT PLATFORM designed to transform the treatment of moving cardiac targets. The company's initial focus is ventricular tachycardia (VT), a life-threatening condition with significant unmet clinical need. CardioKit combines radiation-free, real-time ultrasound heart-motion monitoring, ECG and ultrasound-based cardiac and respiratory gating, and AI-enabled motion prediction to precisely synchronize external-beam treatment with the beating and breathing heart—without a catheter or incision. Compatible with both photon and proton therapy systems, CardioKit is designed as a scalable platform for additional ventricular arrhythmias, broader cardiac ablation applications, and other non-invasive procedures requiring precise motion management. EBAMed plans to treat its first patient in Q4 2026, providing a major near-term clinical and strategic value inflection point.

Aidan Mulloy

Founder & CEO, Eclipse Medical

Eclipse Medical developed Omega, a left atrial appendage closure device for stroke prevention in nonvalvular atrial fibrillation. More than 1,000 devices have been implanted across Europe, and the company is preparing a US IDE pivotal trial, with IDE submission targeted for Q1 2027.

Kelly Huang

CEO, Elucid

Elucid develops AI software for coronary and carotid CT angiography that quantifies and characterizes atherosclerotic plaque to support personalized cardiovascular care. Its FDA-cleared Plaque-IQ™ software provides patient-specific plaque analysis, and the company is pursuing FDA-clearance of its BioIntegrated FFR-CT technology derived from the same plaque input to enable integrated anatomic and functional assessment of coronary artery disease.

Greg Parranto

CEO, Endeavor Orthopaedics

Endeavor Orthopaedics is an IP-protected platform technology company focused on the integration of fracture repair with soft tissue management of deforming forces. The combination of plate/screw and suture construct in one implant allows surgeons to address not only the osseous fracture repair but also the soft-tissue deforming forces, creating a bio-mechanical advantage during patient recovery.

Jason Sun

Co-Founder & Managing Director, Eyerising Interantional

Eyerising International (ERI) has developed and commercialized a home-use, repeated low-level red-light therapy device that not just slows progression but reverses myopia in children. 3 minutes twice a day delivers a first-in-class, non-invasive, drug-free treatment option. The technology is patent protected and backed by 20 completed international clinical trials and more than 30 papers in leading peer-reviewed journals. It is clinically validated as the most effective for all myopia patients and only effective treatment against high myopia. The device holds regulatory approval in more than 40 countries and is in commercial use in more than 10. Recently ERI achieved indication extension to adult patient population, making the device first and only therapy for myopic adults.

Field Medical, Inc. was founded by Dr. Steven Mickelsen to realize the second generation pulsed field ablation therapy system for treatmet of broad heart arrhythmia conditions.

Jennifer Fried

Co-Founder & CEO, Flow Medical

Flow Medical is developing a catheter-directed thrombolysis platform for the treatment of intermediate-risk pulmonary embolism. The device combines thrombolytic drug delivery with continuous pulmonary artery pressure monitoring, enabling real-time assessment of a patient's hemodynamic response during therapy.

John Wong

CEO, Fluid Biomed

Fluid Biomed is developing the world's first bioabsorbable neurovascular stent to cure brain aneurysms

Gabriele Niederauer

CEO & Co-Founder, Freyya

Freyya is developing a tampon-like wearable and companion app that give patients and therapists real-time biofeedback on pelvic floor muscle performance during everyday activities, extending physical therapy beyond the clinic. One in four women has a pelvic floor disorder, and Freyya provides the first objective measurement of pelvic floor muscle function and intra-abdominal pressure outside the clinic and during movement, addressing the poor adherence and limited feedback that hold treatment back.

Neil Bodick, MD, PhD, MBA

Co-Founder, President & CEO, Gate Science

Gate Science is developing RELAY, a novel platform that integrates regional anesthesia and peripheral neuromodulation to provide synergistic control of postoperative pain. Recent randomized, sham-controlled clinical results demonstrated substantial reductions in pain and opioid consumption persisting beyond treatment discontinuation, suggesting the potential to transform perioperative pain management and prevent persistent postsurgical pain.

Eddie Shaw

CEO, Gordian Surgical

Gordian Surgical is developing a portfolio of integrated, open-platform closure technologies for laparoscopic and robotic surgery. Its platform is designed to enable consistent fascial closure across multiple surgical access systems, with a particular focus on platform-agnostic solutions for robotic surgery. Following the recent acquisition of a competing port-closure technology, Gordian is expanding its portfolio through a combination of internal development and strategic partnerships.

Bruce Batten

Founder/CSO, GRIP Molecular Technologies, Inc.

GRIP Molecular Technologies has developed a novel CRISPR-based diagnostic that enables molecular testing in a simple lateral flow format for both point-of-care (POC) and point-of-need (PON) infectious disease testing. The platform delivers test results comparable to existing POC and lab-based molecular tests in under 15 minutes at room temperature, eliminating the need for specialized equipment or laboratory infrastructure. This breakthrough technology positions GRIP to address the growing demand for rapid, accurate, and accessible molecular diagnostics in diverse healthcare settings.

Raj Shah

CEO, GuideAI Health

GuideAI Health automates the early detection of chronic vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts. The platform's first product addresses the 90% underdiagnosis/misdiagnosis rate of peripheral vascular disease in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.

Christopher Lee

Co-Founder & CEO, HapticHeart Solutions

HapticHeart Solutions is advancing a wearable haptic feedback platform—featuring a glove and armband—that restores tactile sensation in catheter-based, minimally invasive, and robotic procedures. By converting physical and physiological signals into real-time touch and force feedback, the system aims to enhance surgical precision, shorten learning curves, and improve patient outcomes. Currently at Technology Readiness Level 6, the prototype has demonstrated clinical utility in electrophysiology and is being expanded for use in robotic surgery.

Mike Connolly

CEO, Healionics

Healionics is developing safer, more reliable means of bloodstream access to support life-saving dialysis therapy in kidney failure patients. Its FDA Breakthrough-designated STARgraft AV graft has 24-month clinical results that show outstanding resistance to both occlusion and infection — the two primary causes of failure in on-market grafts. The company also has a diverse product pipeline leveraging its core STAR biomaterial technology which can inhibit scar tissue encapsulation and infection to improve the performance of a wide range of other implantable devices and facilitate creation of entirely novel ones.

Richard Jones

Founder/CEO, HealthSeers

Cairdio addresses a critical cardiac diagnostic gap by mitigating the limitations inherent in traditional stethoscopes. Our patented platform integrates advanced electronics, strategic four-point acoustic positioning, and AI-driven diagnostics to deliver immediate, clinical-grade cardiac assessments. For cardiac screenings, Cairdio will replace the stethoscope worldwide.

Francis White

CEO, Heart Biotech Holdings

The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body's own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing.

Scott Klein

CEO, HelpWear

HelpWear is striving to better at-home healthcare by developing affordable and accessible products for patients all around the world. HelpWear is currently developing its first product, the HeartWatch, allowing for 24/7 at home heart monitoring with an embedded emergency contact system for furthered prevention and bettered treatment of heart related illness.

Chris Lee

Co-Founder and CEO, Huxley Medical

Huxley Medical's SANSA® diagnostic service helps health systems expand sleep testing access for more than 50 million Americans with undiagnosed and untreated sleep apnea. SANSA combines a multi-sensor chest-worn patch (two dozen issued and pending patents), several FDA-cleared AI diagnostic indications supported by more than 20 publications, and workflow services that allow health systems to seamlessly expand diagnostic capacity starting with home sleep testing.

Adam Clark

CEO, IMRA Surgical

Advanced training for surgeons to enhance the use of minimally invasive robotics in surgery and improve patient outcomes.

Imanuel Lerman

CEO & Founder, InflammaSense

InflammaSense is a medical technology company pioneering a first-of-its-kind AI-driven sepsis monitoring platform that combines Autonomic Neurography (ANG) and micro-RNA profiling to continuously track the body's inflammatory signals in real time. This unique platform detects organ-specific infection signals and triggers precise micro-RNA biomarker tests, providing real-time insights that guide tailored treatment decisions for sepsis. By enabling faster sepsis diagnosis, precision therapy guidance, and significant hospital cost savings through shorter hospital stays, InflammaSense delivers improved patient outcomes and a compelling value proposition for healthcare systems.

Peter Fischer

CEO, Inkspace Imaging

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics.

Rubén Molina

CEO & Co-Founder, INNITIUS

Innitius has developed a quantitative diagnostic platform that measures cervical tissue biomechanics combined with AI models to support clinical decision-making in obstetrics. The technology addresses key use cases including threatened preterm labor, early preterm birth risk stratification, and induction of labor, enabling more accurate and objective assessment at the point of care.

Harlee Sorkin

CEO, InterShunt

InterShunt is developing a minimally invasive catheter therapy for heart failure, the leading cause of hospitalization and Medicare expense. Currently in clinical phase, the procedure dynamically offloads left atrial pressure, addressing the most debilitating symptoms in patients with limited treatment options.

Jeff Chandler

Co-founder, President & CEO, KiriGenX Inc.

KiriGenX is developing the first bioinductive collagen implant platform purpose-built for early-stage rotator cuff disease at the articular side. The technology delivers a biologic scaffold to support tendon healing in an underserved patient population and is advancing through a 510(k) pathway, with planned expansion into broader tendon repair indications.

Kou Watanabe

Founder & CEO, Koutech Medical Robotics

KouTech is a multinational medical robotics company of Japanese origin, pushing the boundaries of precision in microsurgery and supermicrosurgery through its high-precision, platform-based technologies. Leveraging fully integrated, in-house R&D and manufacturing capabilities, KouTech has developed an ultra-compact microsurgical robotic system and an ophthalmic robotic system. Both platforms are paired with proprietary, in-house-designed and manufactured intelligent micro-instruments, including the world's smallest in their category. Engineered for high-magnification surgical environments, these systems deliver submicron motion control. KouTech is building an integrated microsurgical platform that brings together robotic systems, procedure-specific instruments and consumables, and specialized training programs. Its technology supports applications in vascular, lymphatic, nerve, and ophthalmic surgery, as well as complex reconstruction. With a global product development and regulatory roadmap spanning Asia, Europe, and North America, KouTech is positioning its platforms for broader international adoption.

Liquet Medical is developing catheter-based technology for the treatment of pulmonary embolism (PE). Our Versus™ Catheter combines bilateral pulmonary artery drug delivery with continuous, real-time pulmonary artery pressure monitoring through a single venous access, enabling physicians to assess hemodynamic response during catheter-directed thrombolysis.

Dr. Antony Rix

CEO, Lucida Medical

Pi™ is an AI-based medical device software for cancer screening, diagnosis and management. For prostate cancer, Pi™ has CE Class IIb certification, FDA 510(k) approvals granted and pending, and a growing evidence base showing significant increases in overall accuracy and cancer detection.

Ojas Mahapatra

CEO, MARS Bioimaging

MARS Bioimaging brings the world's first mobile, colour CT technology for musculoskeletal care into community/clinics and point-of-care settings. Built on photon-counting CT technology exclusively licensed from CERN, MARS delivers high-resolution, quantitative 3D images with material differentiation to support faster, more confident diagnosis and treatment decisions.

Colby Holtshouse

CEO, May Health

May Health is developing a minimally invasive treatment for polycystic ovary syndrome (PCOS), a leading cause of female infertility due to ovulatory dysfunction. Current treatment options—including drug therapy, surgical ovarian drilling, and IVF—carry risks such as multiple pregnancies, invasiveness, and high costs. May Health's approach aims to replicate the effectiveness of ovarian drilling while reducing procedural risk and invasiveness. The goal is to enable more natural conception pathways for women with PCOS.

Gunter Trojandt

Co-Founder & CEO, MDA - Medical Decision Alliance

MDA is building a best-in-class surgical reference database and translating the expertise of leading surgeons into advanced, AI-powered intra-operative decision-support solutions. Backed by €4 million in seed capital, MDA has successfully validated its business model over the past 24 months. To unlock the full potential of its approach and secure long-term market leadership, MDA is now seeking further growth capital.

Alex Joseph

Commercial Lead, Microsure

Microsure develops MUSA-3, a CE-marked robotic system for open microsurgery and supermicrosurgery. The system scales and tremor-filters the surgeon's hand movements and works with standard microsurgical instruments, enabling procedures on vessels under one millimetre, such as lymphatic reconstruction for lymphedema.

Nico Fenu

Co-founder & CEO, Nami Surgical

Nami Surgical has developed the world's first miniaturized ultrasonic scalpel designed specifically for robotic-assisted surgery and the only ultrasonic technology engineered to articulate through wristed robotic joints. This represents a major unmet need in robotic surgery, where ultrasonic energy solutions remain constrained by size, articulation, and integration limitations.

Ben Holmes

CEO, NANOCHON

Nanochon's Chondrograft™ is a synthetic, off-the-shelf implant designed to treat focal chondral and osteochondral knee defects in active patients. Made from a proprietary polymer blend and 3D-printed to mimic natural cartilage and bone architecture, it provides immediate mechanical support while promoting long-term tissue regeneration—bridging the gap between conservative care and total knee replacement.

Alan Lucas

Co-Founder, CEO, & Director, Navigation Sciences

Navigation Sciences™ is developing the NaviSci™ System to address the growing need for precision surgical oncology in the treatment of soft-tissue cancers.
The NaviSci™ System is designed to support precise, tissue-conserving tumor resection, including in the lung, liver, and head and neck. By integrating augmented reality (AR), advanced software, and surgical instrumentation, the system enables real-time, in vivo surgical measurement to help surgeons remove tumors more precisely while preserving tissue and function and improving workflow.
The National Cancer Institute (NCI) recently selected Navigation Sciences as a 2026–2027 SBIR Showcase Company, recognizing its readiness for investment and strategic partnerships.

Dr. Chinelo Nwaogbo, DNP, APRN, FNP-C, CWS

Founder & CEO, NELO

NELO Smart Sharps System is an intelligent enclosure that retrofits existing sharps containers to help prevent overfilling and reduce needlestick injury risk. The system combines real-time fill-level monitoring, visual status indicators, automatic locking at capacity, and compliance tracking to improve safety and support OSHA-aligned sharps management across healthcare facilities.

George Kramer

CEO, Neocor

NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach. The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery. The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure. CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.

Manfred Franke

CEO, Neuronoff, Inc.

The Injectrode® Platform aims to provide chronic pain patients with an easy way to get relief without drugs or invasive surgeries.

Oliver Piepenstock

CEO & Founder, Noah Labs

Noah Labs Vox eliminates the no. 1 cause of hospital admissions - congestive heart failure - 3 weeks before hospitalization by analyzing voice changes caused by fluid build-up in the lungs and vocal tract. Trained on the world's largest heart failure voice data set, the patented technology is being piloted at Mayo Clinic, UCSF and Charité Berlin.

Barry McCann

Founder & CEO, NUA Surgical

NUA Surgical® is an award-winning Irish MedTech company innovating in Women's Health. Developed out of BioInnovate Ireland and the University of Galway, we've patented the SteriCISION® C-Section Retractor — a single-use, self-retaining retractor improving access and outcomes during Caesarean delivery. Founded in 2018, we're now VC-backed, having closed a €6.5M Series A in December 2024 led by EQT Life Sciences, with Kidron Capital, Texas Medical Center Venture Fund and Enterprise Ireland participating. We're using this to drive regulatory clearance and commercialisation across Europe and the US.

Kath Giles

Managing Director & CEO, OncoRes Medical

OncoRes Medical is a clinical stage company developing a novel imaging modality (QME) that generates microscale maps of tissue stiffness, enabling identification of residual cancer inside the surgical cavity and complete tumour clearance. This advanced imaging technology, focused on breast cancer conserving surgery first, is broadly applicable across the 17 million solid tumours diagnosed globally and can be incorporated into minimally invasive and robotic surgical tools.

Conner Herman

CEO, Percy

Percy is a paradigm-shifting contactless, non-video, multi-sensor behavioral sleep monitoring device with thermal, radar, microphones, and environmental sensors and an AI algorithm that intuits behavioral insights in real time. Doctors access a database where they can access a timeline with objective baseline data to identify episodic problematic events that disrupt sleep, discriminate between medical and behavioral sleep challenges, and monitor treatment compliance without patient report.

Patrick Anquetil

CEO, Portal Instruments, Inc.

Biologics grow in volume and viscosity, pharma companies are pushing to move therapies from infusion to at-home subcutaneous delivery, exposing the limits of traditional spring-based injectors. Portal Instruments is developing software-defined, computer-controlled auto-injectors that actively regulate pressure and flow to enable reliable large-volume delivery across viscosities while supporting a broader range of formulations. By capturing real-time injection data, the NEXUS platform can support adherence and therapy management and serve as a cornerstone for future AI-enabled therapies, positioning drug delivery as both a device and data platform.

Joanna Nathan

CEO & Co-Founder, Prana Surgical

A minimally invasive, lung-sparing device that will provide physicians and patients with the certainty they need to move forward with treatment.

David Carey

CEO, Preceptis Medical

Preceptis Medical develops technologies that enable pediatric ear tube procedures to be performed in the office without general anesthesia. The Hummingbird® Tympanostomy Tube System (TTS) allows ENTs to place ear tubes efficiently under local anesthesia, eliminating the need for an operating room while maintaining established standards of safety and effectiveness for one of the most common pediatric procedures.

Chris Lear

Chief Strategy Officer, Prometheus Therapeutics

Prometheus Therapeutics has developed the world's first Regenerative Photobiomodulation (PBM) platform to stimulate biologic healing. This is a patent-protected technology platform, and our first mission addresses the most significant unresolved clinical issue in Brain Aneurysm Care: awful long-term occlusion rates.

Trey Finch

Co-Founder & CEO, Qubee Medical

Qubee Medical is developing a port and single-use cannula platform for hemodialysis and peritoneal dialysis. The system is designed to reduce access failures, infections, and lower the total cost of care, which are among the largest cost drivers in dialysis treatment.

Carl Daintree

CEO, QV Bioelectronics

QV Bioelectronics is developing GRACE, an implantable Tumour Treating Fields (TTF) device platform for treating solid tumours, initially focusing on glioblastoma (GBM). Placed during tumour resection surgery, GRACE delivers targeted TTF from within the body to disrupt cancer cell division, with an implantable design intended to maximise patient quality of life.

Daniel Walzman

Founder & CEO, Radial1

Radial1 has developed unique endovascular catheter technologies for Neurovascular, Cardiovascular and Peripheral Vascular applications. Full line of stroke aspiration catheters feature the lowest profiles and LARGEST LUMENS in the world. Largest lumen Guide catheters, lowest profile Radial-to-peripheral and Radial-to-brain sheaths, lowest profile diagnostic catheters, and lowest profile access sheaths. Groundbreaking steerable technologies as well. Raising Series A

Michael Nagel

CEO, Raydiant Oximetry

Raydiant Oximetry is a privately held, clinical stage medical technology company aimed at elevating the standard of care for labor and delivery with two fetal pulse oximetry technologies. Leveraging advanced biophotonics and machine learning, fetal pulse oximetry has the potential to reduce risks associated with emergency c-sections and hypoxic events during childbirth. The technology is also compatible with existing monitor platforms, clinical workflows and reimbursement codes.

Justin Sutherland

CEO, Realize Medical

Realize Medical makes patient-specific planning easy with, FDA-cleared Elucis, the world's first all-in-one VR-based medical modeling and collaboration platform. Elucis is a mixed reality software platform for surgical planning that transforms medical images into interactive 3D models. It enables clinicians to visualize, design, and plan complex procedures with precision and collaboration, improving understanding, communication, and patient outcomes.

Mark Pacyna

CEO, Reprieve Cardiovascular

Reprieve Cardiovascular is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients.

Marc Zemel

CEO, Retia Medical

Retia develops healthtech AI algorithms for helping guide management of surgical and critically ill patients to improve outcomes. This is a $4 billion market. The company's technology has been clinically validated and is used in 65 hospitals.

James Lowry

CEO, Ropana Vascular

Ropana Vascular develops endovascular devices to fill significant unmet clinical needs in the treatment of cardiovascular disease. Our first innovation is a truly forward emitting peripheral IVL technology for crossing calcified occlusions. We are wrapping up our seed round currently and are chartered to bring our FirstPass(tm) catheters through the FDA in the coming 24-36 months.

Olivier Delporte

CEO, SamanTree Medical

SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory.

Maria Artunduaga

CEO, Samay

Samay's Sylvee is the first wearable to match CT performance, the gold standard, for early COPD detection, identifying small airway disease up to 5 years before spirometry can detect any changes. Validated in 450+ patients (AUC 0.93) and protected by 18 patents across 20+ countries, Samay is already generating revenue with a top European respiratory pharma, a world-leading sleep company, and a top US academic medical center, while preparing for a late 2027 launch across 1,500 clinics through Latam's third-largest payer and investor.

Richard Hanbury

CEO, Sana Health

Sana Health is a prescription audiovisual neuromodulation device that delivers rhythmic light and sound in guided 16-minute at-home sessions for chronic pain, PTSD, and sleep. The device holds FDA De Novo authorization (Jan 2026) and Health Canada clearance (Aug 2025) for neuropathic pain. A closed-loop PPG biosensor reads heart rate variability for real-time session personalisation and clinician remote monitoring.

Ashissh Raichura

Founder & CEO, Scanbo Technologies

Scanbo develops connected point-of-care diagnostic devices and clinical AI software for primary care, pharmacies and community health settings. Its D8 device combines blood pressure, single-lead ECG, oxygen saturation, temperature and other vital measurements with finger-prick glucose testing in one device. The platform connects these measurements to digital patient records and clinical decision-support tools.

Bart Bandy

CEO, Solenic Medical

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants.

Anders Sideris

CEO & Co-Founder, Somnair

Somnair is a first-in-class, non-invasive neurostimulation oral appliance for the treatment of obstructive sleep apnea. The custom-fitted device stimulates a novel neuroanatomical target to maintain airway patency during sleep. Somnair's technology is designed for convenient at-home use.

Jim Fidacaro

CEO, Sonion Health

Sonion Health is dedicated to revolutionizing hypertension care through our cutting-edge optical biosensing technology and artificial intelligence, enabling a cuffless wearable device that provides continuous access to clinical-grade blood pressure monitoring. This device offers real-time, precise readings throughout daily activities—including sitting, semi-fowler, and supine—setting new benchmarks in hypertension diagnosis, remote patient monitoring (RPM), and inpatient care.

Cynthia Perazzo

President & Co-Founder, Sovato

Sovato is a healthcare technology company with a vision to create access to the highest quality surgery and procedures for everyone, everywhere—reaching the more than five billion people worldwide who lack access to expert clinical care. Sovato enables healthcare organizations to deploy and scale remote surgery and procedure programs through a single, integrated platform that connects sites, specialties, and any remote-enabled robotic or device system within a growing global network. Backed by over 20 issued and pending patents, Sovato is working with healthcare and industry partners to scale remote surgery and procedures as a new model of care.

Dimitri Sokolov

CEO, Spiro Robotics

Spiro Robotics is developing an innovative handheld robot intended to automate airway management in patients requiring tracheal intubation.

Tarek Makansi

CEO & CTO, StimAire

StimAire's patented technology is an injectable, rice-grain sized neurostimulator (combined with a small wearable) for treating Obstructive Sleep Apnea, a $30B market. Replacing major surgery with a 15-minute injection is expected to lead to worldwide reimbursement and full market acceptance. This technology has shown feasibility and safety in humans in 2023, has shown repeatability and chronic performance in animals in 2025, and was awarded FDA Breakthrough Device Designation in 2024.

Amir Soltanianzadeh

CEO, StimCardio Medical

StimCardio Medical (formerly CardiaCare) is a medical device company developing a non-invasive, wearable neuromodulation platform designed to support patients with atrial fibrillation. The StimCardio system integrates continuous physiological monitoring, advanced signal analysis, and personalized peripheral neuromodulation with the goal of restoring autonomic balance and improving heart–brain communication. StimCardio is advancing a patient-centric, home-based approach to arrhythmia management that complements existing clinical care pathways.

Madhu Ayyagari

CEO, TECLens

The TECLens innovative treatment utilizes proprietary quantitative corneal cross-linking (qCXL™) technology and the CXLens® device to gently strengthen and reshape the cornea, designed to redefine vision correction for refractive errors, including restoring near vision for those with presbyopia. The procedure aims to be comfortable, non-invasive, in-office treatments. TECLens is also exploring future applications for hyperopia, progressive myopia in children and low-order myopia in adults, keratoconus, and pseudophakic corrections, promising a brighter future for vision correction.

Justin Anderson

Chief Executive Officer, President, and Chairman, Tensor Surgical

Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company's portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures.

Zeeshan Syedain

CEO, Vascudyne

Vascudyne is building living blood vessels and heart valves devices that come off the shelf. Its bioengineered tissue platform turns human cells into vascular grafts and valves that surgeons can store and implant like any other device, with no custom manufacturing and no waiting. The goal is a durable, lifelong solution for patients with heart and vascular disease.

Rob Krummen

CEO, Vektor Medical, Inc.

Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.

Adam Gridley

CEO, Vergent Bioscience

Vergent's lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

Finbar Dolan

CEO, VERSONO Medical

Versono is developing an intravascular ultrasonic platform to improve the crossing of severe occlusions in the peripheral vasculature. The device will prepare a working lumen to support endovascular therapy in patients with chronic total occlusions (CTOs) and critical limb ischemia (CLI).

Manning Hanser

CEO & Co-Founder, Von Vascular, Inc.

Von Vascular is developing the ALGO Smart Pump, a sterile, single-use, software-controlled aspiration system for mechanical thrombectomy in acute ischemic stroke. The platform incorporates real-time pressure sensing and Adaptive Pulsatile Aspiration (APA) technology to manage clot extraction and is designed to operate with any commercially available aspiration catheters. Von's technology roadmap also includes procedural data collection and digital clinical decision-support capabilities.

Mark Goldin

President & CEO, WaveClear Vascular

WaveClear Vascular is developing a catheter-based ultrasonic cavitation platform to treat two conditions currently addressed by separate device categories: venous thrombosis and arterial calcification. A single 6F catheter delivers millions of controlled micro-pulses per minute to fracture calcified lesions and clear blood clots, with minimal blood loss, continuous physician control, and built-in targeted drug delivery.

Lakshmi Dasi

Co-Founder & CTO, YoungHeartValve

YoungHeartValve is developing a fully synthetic, polymer-based transcatheter aortic valve designed to deliver lifelong durability without the need for chronic anticoagulation. The company is advancing its transcatheter aortic valve platform to address one of structural heart's most persistent trade-offs: durability versus safety. The system is currently in the advanced preclinical stage, with ongoing chronic large-animal studies and a latest design that has met regulatory bench-testing requirements for valve performance and mechanical durability. The team has implemented a soft design freeze incorporating physician feedback from earlier acute implantations to optimize both hemodynamic performance and procedural usability.